ADIM
BCRX icon

Alpha DNA Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Alpha DNA Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-58,898
Closed -$448K – 195
2024
Q3 		$448K Buy
+58,898
New +$448K 0.17% 142

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Alpha DNA Investment Management's BCRX Position: Q4 2024 in Review

Alpha DNA Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2024, closing a stake of 58,898 shares — an estimated $448K sold.

Alpha DNA Investment Management first reported a position in BCRX in Q3 2024 and held it in 1 quarter. The position peaked at $448K in Q3 2024. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

  • Alpha DNA Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 58,898 BioCryst Pharmaceuticals shares in Q4 2024, an estimated $448K.
  • Alpha DNA Investment Management first reported a position in BioCryst Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Alpha DNA Investment Management's BioCryst Pharmaceuticals position peaked at $448K in Q3 2024.
  • 258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on Alpha DNA Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.